PD‐L1 expressed on solid tumor cells interacts with PD‐1 on tumor‐infiltrating lymphocytes (TILs) to impair the function and activation of immune cells and trigger tumor immune escape.[4, 5] Overexpression of PD‐L1 is associated with immune escape and poor prognosis in tumor.[6] Therefore, identification of distinct mechanisms in the modulation of PD‐L1 expression and function may provide a molecular basis to improve the clinical efficacy of tumor immunotherapy by targeting PD‐L1. This evidence concerns the gene CD274 and neoplasm.